Insights
Search Results
Client Highlights
5.07.26
Wilson Sonsini Advises Astranis on $450 Million Fundraise
On May 6, 2026, Astranis, an advanced satellite manufacturer, announced it has raised $450 million in new capital, bringing the company’s total raised to more than $1.2 billion as it scales to meet increased demand for its spacecraft designed for geostationary orbit and other high orbits. The funding includes a new $300 million Series E round co-led by Snowpoint Ventures and Franklin Templeton, with participation from Andreessen Horowitz, funds and accounts managed by affiliates of BlackRock, Baillie Gifford, and Fidelity Management & Research Company, as well as BAM Elevate, Nimble Partners, and Friends & Family Capital, along with other existing and new investors. A delayed-draw credit facility by Trinity Capital adds up to $155 million of additional capital to support the addition of new manufacturing capacity and support future growth. Wilson Sonsini Goodrich & Rosati advised Astranis on the transactions.
Client Highlights
4.09.26
Firm Advises Marvell Technology on Strategic Partnership and $2 Billion Investment from NVIDIA
On March 31, 2026, NVIDIA announced it has invested $2 billion in Marvell Technology as part of a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™. This partnership offers customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The companies will also collaborate on silicon photonics technology. Wilson Sonsini Goodrich & Rosati advised Marvell on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises OnKure Therapeutics on $150 Million Private Placement
On March 27, 2026, OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel precision medicines, announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. Wilson Sonsini Goodrich & Rosati advised OnKure on the transaction.
Newsletters
3.04.26
The Scramble: 2025 Gaming Legal Year in Review
Wilson Sonsini is pleased to present The Scramble: 2025 Gaming Legal Year in Review. This annual publication offers a retrospective look at the game industry’s legal landscape of the past year, showcases Wilson Sonsini’s contributions during that period, delivers insightful industry analyses, and anticipated trends.
Newsletters
1.29.26
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q3/Q4 2025
Wilson Sonsini’s All Eyes on AI: Regulatory, Litigation, and Transactional Developments closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deals highlights, firm publications, and other AI and machine learning highlights. This latest Q3/Q4 2025 edition features:
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
Client Highlights
10.02.25
Wilson Sonsini Advises Kodiak AI on Completed Business Combination with Ares Acquisition Corporation II
On September 29, 2025, Kodiak AI, a leading provider of AI-powered autonomous vehicle technology, announced that Kodiak Robotics, Inc. successfully completed its business combination with Ares Acquisition Corporation II (AACT), a publicly traded special purpose acquisition company. The business combination was approved by AACT shareholders on September 23, 2025. In connection with the closing, AACT was renamed Kodiak AI. Kodiak AI’s common stock and public warrants began trading on Nasdaq on September 25, 2025, under the ticker symbols “KDK” and “KDKRW,” respectively. Wilson Sonsini Goodrich & Rosati advised Kodiak AI on the transaction.
Client Highlights
9.17.25
Firm Advises Planet Labs on $460 Million Convertible Senior Notes Offering
On September 12, 2025, Planet Labs, PBC, completed an upsized offering of $460 million aggregate principal amount of convertible senior notes due 2030, in a private transaction. The offering amount included the exercise in full of the option that Planet Labs had granted to the initial purchasers to purchase up to an additional $60 million of notes. In connection with the offering, Planet Labs entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions. Wilson Sonsini Goodrich & Rosati advised Planet Labs on the transaction.
Newsletters
9.09.25
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q2 2025
The latest edition of All Eyes on AI addresses the White House’s AI Action Plan, the USPTO’s plan to accelerate patent review, the EC’s details of the EU AI Act for GPAI requirements, and the Japanese market’s study on generative AI markets.
Client Highlights
8.28.25
Wilson Sonsini Advises Uniphore on Orby AI and Autonom8 Transactions
On August 28, 2025, Uniphore, the Business AI company, announced that it has acquired Orby AI, Inc. and intends to acquire Autonom8, Inc., two AI-native companies that will enhance the capabilities of Uniphore’s Business AI Cloud. Both teams bring top AI research and engineering talent from DeepMind and Google, adding unmatched expertise and proven innovation to push the boundaries of Business AI. Wilson Sonsini Goodrich & Rosati advised Uniphore on both transactions.
Client Highlights
8.20.25
Wilson Sonsini Advises Upstart on $690 Million Convertible Senior Notes Offering
On August 14, 2025, Upstart Holdings, Inc. completed an upsized offering of $690 million aggregate principal amount of convertible senior notes due 2032 in a private transaction. The offering amount included the exercise in full of the option that Upstart had granted to the initial purchasers to purchase up to an additional $90 million of notes. In connection with the offering, Upstart entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.